sunitinib silver 50 mg cápsulas duras efg
silver pharma s.l. - sunitinib malato - cÁpsula dura - 50 mg - sunitinib malato 50 mg - sunitinib
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agentes antineoplásicos - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib 50 mg
lotus pharmaceuticals co. ltd - sunitinib (eq. a 66,8 mg de malato de sunitinib) - cápsula - 50 mg
sunitinib 125 mg
lotus pharmaceuticals co. ltd - sunitinib (eq. a 16,7 mg de malato de sunitinib) - cápsula - 12,5 mg
sunitinib 25 mg
lotus pharmaceuticals co. ltd - sunitinib (eq. a 33,4 mg de malato de sunitinib) - cápsula - 25 mg
sunitinib cápsulas 50 mg
siron pharma s.p.a. - sunitinib - sin formulas
sunitinib cápsulas 12,5 mg
siron pharma s.p.a. - sunitinib - sin formulas
sunitinib cápsulas 25 mg
siron pharma s.p.a. - sunitinib - sin formulas
sunitinib cápsulas 12,5 mg
logistics business services chile s.p.a. - sunitinib - sin formulas
sunitinib cápsulas 25 mg
logistics business services chile s.p.a. - sunitinib - sin formulas